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Polymorphisms of genes involved in extracellular
matrix remodeling and abdominal aortic aneurysm
Claudia Saracini, PhD,a Paola Bolli, PhD,a Elena Sticchi, PhD,a,b Giovanni Pratesi, MD,c
Raffaele Pulli, MD,d Francesco Sofi, PhD,a Carlo Pratesi, MD,d Gian Franco Gensini, MD,a,b
Rosanna Abbate, MD,a and Betti Giusti, PhD,a Florence and Rome, Italy
Background:Abdominal aortic aneurysm (AAA) has amultifactorial etiology and the relevance of genetic factors is getting
increasing interest, in particular those related to the destructive remodeling of extracellular matrix.
Methods: We performed a candidate gene association study of polymorphisms in genes coding matrix metalloproteinases
(MMPs), tissue inhibitors of MMPs (TIMPs), and elastin (ELN) in AAA. DNA samples from 423 AAA patients and 423
controls were genotyped for 12 polymorphisms in 10 genes: MMP1 (1607G/GG), MMP2 (735C/T; 1306C/T;
1575 G/A), MMP3 (5A/6A), MMP9 (1562C/T), MMP10 (A180G), MMP-12 (82A/G), MMP-13 (77A/G),
TIMP1 (C434T), TIMP3 (1296T/C), and ELN (G1355A).
Results:Genotype distribution was significantly different between patients and controls for the following polymorphisms:
1306C/TMMP2; 5A/6AMMP3;77A/GMMP-13; G1355A ELN; and C434T TIMP1. In a multivariable logistic
regression analysis adjusted for traditional cardiovascular risk factors and chronic obstructive pulmonary disease,
1306C/T MMP2 (odds ratios [OR]  0.55 [95% confidence interval, CI .34-.85], P < .007) and G1355A ELN
(OR 0.64 ([95% CI .41-.99], P .046) polymorphisms resulted in independent protective factors for abdominal aortic
aneurysm (AAA), whereas 5A/6A MMP3 (OR  1.82 [95% CI 1.04-3.12], P  .034) and 77 A/G MMP-13 (OR 
2.14 [95% CI 1.18-3.86], P  .012) polymorphisms resulted in independent risk factors for AAA. In a multivariable
logistic regression analysis adjusted for traditional cardiovascular factors and chronic obstructive pulmonary disease, the
prevalence of the contemporary presence of three or four genetic risk conditions was a strong and independent determinant
of AAAdisease (OR 2.96, 95%CI 1.67-5.24, P< .0001). For those polymorphisms independently associated with AAA
in this study (1306C/T MMP2, 5A/6A MMP3, 77A/G MMP-13, and G1355A ELN polymorphisms), we
performed a meta-analysis of the available data (this paper and literature data). We found a significant association with
an increased risk of AAA for MMP3 (AAA patients n  1258, controls n  1406: OR  1.48 [95% CI  1.23-1.78],
I2  0%) and MMP-13 (AAA patients n  800, controls n  843: OR  1.37 [95% CI  1.04-1.82], I2  25%)
polymorphisms and a trend that did not reach the statistical significance, toward a decreased risk of AAA forMMP2 (AAA
patients n  1090, controls n  1077: OR  0.83 [95% CI  .60-1.15], I2 7 1%) and ELN (AAA patients n  904,
controls n  1069: OR  0.79 [95% CI  .53-1.18], I2  72%) polymorphisms.
Conclusions:These findings suggest that polymorphisms inMMP2,MMP3,MMP-13, and ELN genes may independently
contribute to the pathogenesis of AAA. (J Vasc Surg 2012;55:171-9.)
Clinical Relevance: This study identifies polymorphisms inMMP2,MMP3,MMP-13, TIMP1, and ELN genes as genetic
markers of abdominal aortic aneurysm (AAA) and underline the need to concentrate our efforts in studying the role of
these markers in the aneurysmal disease to improve the understanding of its pathophysiology and pathogenesis. This
study is part of the task for the identification of AAA genetic susceptibility factors, fundamental to design and develop
gene-based clinical studies in the future to validate diagnostic or prognostic scores based on clinical, biochemical, genetic,
and proteomic information to be applied in the everyday clinical practice.
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0Abdominal aortic aneurysm (AAA) represents a se-
vere chronic degenerative condition associated with ath-
erosclerosis and characterized by segmental weakening
and dilation of the aortic wall. AAA occurs in up to 9% of
humans 65-years-old. It is estimated to be the tenth
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dommonest cause of mortality and is responsible for2%
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The pathogenesis of this complex disorder is the result
f the interactions among multiple genes end environmen-
al factors, but it has not been completely clarified yet.
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January 2012172 Saracini et alA key mechanism in the pathogenesis and progression
of AAA is the proteolytic degradation of the aortic wall;
both increased elastase and collagenase activity have been
found in aortic aneurysms, and both have been positively
correlated with diffuse alterations of extracellular matrix
(ECM) composition and aneurysm size.2,3 Several studies
reported an increased expression and activity of matrix
metalloproteinases (MMPs) in aortic aneurysm tissues and
an imbalance between MMPs and their inhibitors (TIMPs)
that may alter the equilibrium towards aortic wall matrix
degradation.4
In knockout mice models of AAA, the absence of
MMP2 and MMP9 is associated with a lower incidence of
AAA.5 Previous studies have found that different MMPs
(MMP1, MMP2, MMP3, MMP9, and MMP-12) are ex-
pressed at elevated levels in aortic aneurysm compared with
normal vessel wall.3 On the other hand, decreased levels of
TIMPs have been reported in aortic aneurysms.6 In exper-
imental models, inhibitors of MMPs, MMPs gene disrup-
tion,7 or the overexpression of TIMPs may block aneurysm
development.8 Moreover, an ECM composition perturba-
tion, due to structural protein alteration, could weaken the
aortic vessel wall, and, consequently, determine a major
tendency to aneurysmal disease.
Family history is a well-known risk factor for AAA.
However, it remains unclear which genetic factors influence
the formation of AAA in individuals who do not have
genetic syndromes or a familial AAA.9,10
Altered levels of MMPs and TIMPs may be due to
differences in the genetic sequences coding these enzymes.
Genetic variations can influence the transcription of these
genes or the function of the coded proteins. Indeed, func-
tional studies have shown that many of the promoter vari-
ants in MMP genes determine differential binding of tran-
scriptional factors.11
Several candidate genes (MMP3, MMP9, TIMP1, and
TIMP2) have been investigated in different ethnic groups
to identify a possible association between genetic variants
and the sporadic AAA phenotype often in small cohorts of
patients and with discordant results.10-13
As previous studies carried out in AAA cohorts of
patients provided no definitive results on the association
of different polymorphisms in different genes involved in
ECM remodeling with AAA, the aim of our study was to
evaluate the genetic susceptibility to AAA conferred by
12 polymorphisms in 10 genes coding enzymes involved
in the ECM remodeling (MMP1, MMP2, MMP3,
MMP9, MMP10, MMP-12, MMP-13, TIMP1, TIMP3,
and elastin [ELN]).
METHODS
Study population. We enrolled 423 consecutive pa-
tients with AAA referred to the Vascular Surgery Unit of
the University of Florence. Familial and inflammatory
AAAs were excluded from the study. Familial genetic pat-
terns might influence the predictive value of the gene
polymorphisms that are included in this study. In several
studies, some differences were reported between AAA pa- fients with or without a first degree relative with a history of
AA, ie, higher prevalence of male and higher mean age in
onfamilial.14 All controls had a negative personal and
amilial history of AAA. Patients and control subjects in-
luded in this study were previously investigated for poly-
orphisms involved in the methionine metabolism.15 Def-
nitions of the studied populations were detailed in a
revious article.15 At the duplex scanning examination, few
ontrols (10/423) showed aortic diameters between 3 and
.70 mm. We did not exclude these subjects as this situa-
ion could be more representative of the general control
opulation, even if it could mitigate the significance of the
ssociations. Therefore, we compared patients with AAA
eferred to the Vascular Surgery Unit of the University of
lorence for surgery with the control subjects.
Patients and controls gave informed consent and the
tudy was approved by the Ethical Committee.
DNA extraction. Genomic DNA was isolated from
enous peripheral blood by using FlexiGene kit (Qiagen,
ilden, Germany).
Genotyping. We studied 12 polymorphisms in 10
andidate genes involved in ECM remodeling according to
heir demonstrated or putative function based on literature
ata and localization in functional gene regions, extracted
rom Single Nucleotide Polymorphism database (dbSNP)
CBI (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
bsnp&cmdsearch&term). Selection of the poly-
orphisms was also performed to better clarify contrasting
ata available in literature on the role of polymorphisms in
MPs, TIMPs, and ELN in AAA onset and progression.
Polymorphisms information were assessed in dbSNP
CBI and ENSEMBL (http://www.ensembl.org/index.
tml) databases. In Table I, information on the 12 selected
olymorphisms are reported.
MMP1 (rs1799750), MMP2 (rs2285053, rs243865,
s243866), MMP10 (rs486055), MMP-12 (rs2276109),
MP-13(rs2252070),TIMP1(rs4898),TIMP3(rs9619311),
ndELN(rs2071307) polymorphisms were analyzed by using
enomeLab SNPstream genotyping platform and software
Beckman Coulter, Fullerton, Calif).16 In Table A (online
nly; supplementary data), the sequences of polymerase chain
eaction (PCR) and extension oligonucleotides are reported.
MMP3 (rs3025058) and MMP9 (rs3918242) poly-
orphisms were genotyped byNanogene electronic micro-
hip technology.17 In Table B (online only; supplementary
ata), the sequences for PCR and hybridization oligonu-
leotides are reported.
Data analysis. Statistical analysis was performed using
he SPSS package v11.5 (SPSS, Inc, Chicago, Ill). Hardy–
einberg equilibrium (HWE) was evaluated by 2 test.
WE is commonly used for quality control of genotyping:
t indicates inbreeding, population stratification, and sys-
ematic genotyping errors in unrelated individuals. Geno-
ype distributions were compared between AAA and con-
rol groups or between patients with and without other
therosclerotic localizations by 2 analysis. We assessed the
ssociation between each polymorphism and AAA using dif-
erent genetic models. The dominant model compares indi-
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Volume 55, Number 1 Saracini et al 173viduals with one or two rare alleles (heterozygotes
homozygotes) with the group of homozygous subjects. The
recessive model compares individuals with two rare alleles
(homozygotes) with the combined group of heterozygous
wild-type homozygous subjects. The additive model assumes
that there is a linear gradient in risk between the three geno-
types. Categorical variables are expressed as frequencies and
percentages. Unless otherwise indicated, data are given as
median and range. Post-hoc sample size calculations indicated
that a number of 423 AAA patients and 423 controls have a
statistical power () to detect a significant difference in per-
centages of genotypes of 6% for MMP1 (1607G/GG),
21%, 73%, and36% for735C/T,1306C/T,1575G/A
MMP2, respectively, 84% for MMP3 (5A/6A), 7% for
MMP9 (1562C/T), 5% for MMP10 (A180G), 12% for
MMP-12 (82A/G), 78% for MMP-13 (77A/G), 96%
for TIMP1 (C434T), 42% for TIMP3 (1296T/C), and
74% for ELN (G1355A), with an   .05. Comparisons of
continuous variables (age, aortic diameter) between pa-
tients and controls or among genotypes were performed by
the nonparametric Mann–Whitney or Kruskal–Wallis test.
Multivariable logistic regression analysis was used to esti-
mate OR and 95% confidence intervals (CI) for the risk of
AAA. To evaluate if polymorphisms were independently
associated with AAA, multivariable analyses were adjusted
for traditional risk factors for AAA: age, gender, hyperten-
sion, diabetes mellitus, dyslipidemia, smoking habit, and
chronic obstructive pulmonary disease (COPD). The asso-
ciation between polymorphisms, which were significantly
associated with AAA and aortic diameter, was estimated by
Table I. Polymorphisms investigated
Gene symbol and
chromosome position Ensemble gene ID dbSNP ID
MMP1 ENSG00000196611 rs179975
11q22-q23
MMP2 ENSG00000087245 rs228505
16q13-q21 rs243865
rs243866
MMP3 ENSG00000149968 rs302505
11q22.3
MMP9 ENSG00000100985 rs391824
20q12-q13
MMP10 ENSG00000166670 rs486055
11q22.3
MMP12 ENSG00000110347 rs227610
11q22.2-11q22.3
MMP13 ENSG00000137745 rs225207
11q22.3
TIMP1 ENSG00000102265 rs4898
Xp11.3-p11.23
TIMP3 ENSG00000100234 rs961931
22q12.1-q13.2
ELN ENSG00000049540 rs207130
7q11.1-q21.1
ID, Identification number.general linear model. To reduce type I error, we applied the aalse discovery rate (FDR) multiple testing correction in all
tatistical analyses. A value of P  .05 was chosen as the
ut-off level for statistical significance.
For meta-analyses, we pooled results from the individ-
al studies by using Review Manager (RevMan) software
or Macintosh (v5.0) by the Cochrane Collaboration and
tatistical Package for Social Sciences (SPSS) software for
indows (v13.0). The results of each study were reported
s dichotomous frequency data. We used a random-effects
odel that accounts for interstudy variation and provides a
ore conservative effect than the fixed model. Thus, we
alculated random-summary OR with 95% CI, by using
nverse-variance method. The potential sources of hetero-
eneity were assessed by using the Cochrane’s Q test to
ssess between-study differences and the I2 statistic to
uantify the proportion of inconsistency across the study
esults.
ESULTS
Subjects. Demographic and clinical characteristics of
nvestigated subjects are reported in Table II. As expected,
ased on selection criteria, no differences in gender and age
etween AAA patients and controls were observed; statis-
ically significant differences were found in cardiovascular
isk factors such as smoking habit, hypertension, dyslipide-
ia, and COPD, as well as in the prevalence of coronary
rtery, and cerebrovascular and peripheral obstructive ar-
ery disease (Table II).
Single nucleotide polymorphism (SNP) analysis. In
able III genotype distributions of the 12 polymorphisms
Common polymorphism name Position in gene region
1607G/GG 5= near gene
735C/T 5= near gene
1306C/T 5= near gene
1575G/A 5= near gene
5A/6A 5= near gene
1562C/T 5= near gene
A180G exon 2
Lys53Arg
82A/G 5= near gene
77A/G 5= near gene
C434T exon 5
Phe124Phe
1296T/C 5= near gene
G1355A exon 20
Ser422Gly0
3
8
2
9
0
1
7nd 2 analysis by different genetic models are reported.
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in AAA patients and controls.
Genotype distribution was significantly different be-
tween patients and controls for the following polymor-
phisms: rs243865 MMP2, rs3025058 MMP3, rs2252070
MMP-13, rs4898 TIMP1, and rs2071307 ELN.
Carriers of the T allele of the 1306C/T (rs243865)
MMP2, of the A allele of the Ser422Gly (rs2071307) ELN,
and of the C allele of the T434C (rs4898) TIMP1 poly-
morphism had a decreased risk of AAA (Table III). The
status of carriers of the 5A allele of the 5A/6A (rs3025058)
MMP3 polymorphism, as well as the presence of the G
allele at the homozygous status for the 77A/G
(rs2252070) MMP-13 polymorphism represented risk fac-
tors for AAA (Table III).
In a multivariable logistic regression analysis with AAA
as dependent variable and age, gender, hypertension, dia-
betes mellitus, dyslipidemia, smoking habit, COPD and the
single polymorphisms as independent variables (Table IV),
rs243865MMP2 (OR 0.55 [95% CI .34-.85], P .007)
and rs2071307 ELN (OR  0.64 [95% CI .41-.99], P 
.046) gene polymorphisms were independent protective
factors for AAA, whereas rs3025058 MMP3 (OR  1.82
[95% CI 1.04-3.12], P  .034) and rs2252070 MMP-13
(OR 2.14 [95%CI 1.18-3.86], P .012) gene polymor-
phisms were independent risk factors for AAA. Similar
results were also observed in the comparison of AAA pa-
tients and controls, both free from other localization of
atherosclerosis (coronary artery disease [CAD], cerebrovas-
cular disease [CVD], and peripheral obstructive artery dis-
ease [POAD]) (data not shown).
No statistical differences in the genotype distribution of
rs243865 MMP2, rs3025058 MMP3, rs2252070 MMP-
13, rs4898 TIMP1, and rs2071307 ELN gene polymor-
phisms were observed between AAA patients with or with-
out other manifestations of atherosclerosis by 2 (Table V).
Table II. Demographic and clinical characteristics of
AAA patients and controls15
Controls
(n  423)
AAA patients
(n  423) P
Age 72.0 (41-94) 73.5 (40-94) .651
Sex (male) N (%) 366 (86.5) 376 (88.9) .295
Smoking N (%) 267 (63.1) 366 (86.5) .0001
Diabetes N (%) 49 (11.6) 41 (9.7) .372
Hypertension N (%) 179 (42.3) 302 (71.4) .0001
Dyslipidemia N (%) 50 (11.8) 195 (46.1) .0001
COPD N (%) 66 (15.6) 311 (73.5) .0001
CAD N (%) 107 (25.3) 163 (38.5) .0001
CVD N (%) 38 (9.0) 111 (26.2) .0001
POAD N (%) 67 (15.8) 118 (27.9) .0001
Aortic diameter (mm) 19 (12-47) 50 (31-98) .0001
SEM 0.48 SEM 0.58
AAA, Abdominal aortic aneurysm; CAD, coronary artery disease; COPD,
chronic obstructive pulmonary disease; CVD, cerebrovascular disease;
POAD, peripheral obstructive artery disease; SEM, standard error mean.We obtained similar results also in a multivariable logistic segression analysis adjusted for the traditional cardiovascu-
ar risk factors and COPD.
Concerning the effect of the polymorphisms on aortic
iameters, none of the polymorphisms influenced the aor-
ic diameters in patients and controls (data not shown).
Meta-analysis of polymorphisms independently as-
ociated with AAA in this study. For those polymor-
hisms independently associated with AAA in this study
1306C/TMMP2, 5A/6AMMP3,77A/GMMP-13,
nd Ser422Gly ELN polymorphisms), we performed a
eta-analysis of the available data (Table VI). We found a
ignificant association with an increased risk of AAA for
MP3 (AAA patients n 1258, controls n 1406: OR
.48 [95% CI 1.23-1.78], I2 0%) and MMP-13 (AAA
atients n 800, controls n 843: OR 1.37 [95% CI
.04-1.82], I2 25%) polymorphisms and a trend that did
ot reach the statistical significance toward a decreased risk
f AAA for MMP2 (AAA patients n  1090, controls n 
077: OR  0.83 [95% CI  .60-1.15], I2  71%) and
LN (AAA patients n  904, controls n  1069: OR 
.79 [95% CI  .53-1.18], I2  72%) polymorphisms.
Combination of genetic risk conditions. To evaluate
he effect of the combination of the different genetic risk
onditions, we evaluated the association with AAA of the
umber of genetic conditions present for each subject.
enetic risk conditions were considered: CC genotype for
1306C/T MMP2 polymorphism, 5A allele for the
A/6A MMP3 polymorphism, GG genotypes for the
77A/G MMP-13 polymorphism, and GG genotypes for
he Ser422Gly ELN polymorphism. The prevalence of
arriers of three or four genetic risk conditions was signifi-
antly higher in AAA patients (125/423, 29.6%) than in
ontrols (83/423, 19.6%), P  .0001. In a logistic regres-
ion analysis adjusted for traditional cardiovascular risk
actors and COPD, the prevalence of the contemporary
resence of three or four genetic risk conditions was a
trong and independent determinant of AAA disease
OR  2.96, 95% CI 1.67-5.24, P  .0001).
ISCUSSION
The results of the present study suggest that polymor-
hisms in genes coding for important extracellular matrix
omponents, MMP2, MMP3, MMP-13, and ELN are
ndependently associated with AAA, extending and high-
ighting the role of these polymorphisms per se and, for the
rst time, in combination in the pathogenesis of the aneu-
ysmal disease.
To favor the comparison with previous studies, we
ummarized results obtained in this article and literature
ata in Table VI.
In our study, the presence of the T allele of the poly-
orphism1306C/T in the promoter of theMMP2 gene
as associated to a significant and independent protective
ole for AAA. MMP2, also known as type IV collagenase or
elatinase (72-kDa), is an enzyme that specifically cleaves
ype IV collagen, the major structural component of base-
ent membranes. Animal models and human aortic wall
tudies have suggested a role forMMP2 in the pathogenesis
f
i
M
d
(
t
disease
oking
JOURNAL OF VASCULAR SURGERY
Volume 55, Number 1 Saracini et al 175of AAAs.18 The1306 C/T polymorphism of the MMP2
affects the binding of estrogen receptor and the SP1 tran-
scription factor, and it has an allele-specific effect on the
activity of the promoter in driving gene expression.19,20 A
previous article investigated the role of this polymorphism
in AAA incidence, but no significant association between
this genetic variant and AAA was observed.21 The discor-
Table III. Genotype distribution and allele frequency of t
control subjects
SNP
Genotypes (%) Min
alle
frequPatients (n  423)
MMP1
rs1799750 AA(26.0) AG(49.1) GG(24.9) G  .4
MMP2
rs2285053 CC(71.2) CT(27.2) TT(1.6) T  .1
rs243865 CC(64.9) CT(31.0) TT(4.1) T  .1
rs243866 GG(67.2) GA(29.5) AA(3.3) A  0
MMP3
rs3025058 5A/5A
(26.5)
5A/6A
(54.7)
6A/6A
(18.8)
6A  0
MMP9
rs3918242 GG(73.9) GA(23.1) AA(3.0) A  0
MMP10
rs486055 CC(95.4) CT(4.3) TT(0.3) T  .0
MMP-12
rs2276109 AA(78.1) AG(19.1) GG(2.9) G  .1
MMP-13
rs2252070 AA(34.8) AG(43.9) GG(21.4) G  .4
TIMP1
rs4898 TT(100.0) CT(0.0) CC(0.0) C  .0
TIMP3
rs9619311 TT(41.9) CT(44.4) CC(13.7) C  .3
ELN
rs2071307 GG(39.9) GA(43.8) AA(16.3) A  0
AAA, Abdominal aortic aneurysm; SNP, single nucleotide polymorphism.
P values were adjusted by using the false discovery rate (FDR) multiple-test
aP  according to the additive model.
bP  according to the recessive model.
cP  according to the dominant model
Table IV. Odds ratios for the occurrence of AAA accordin
MMP13, and rs2071307 ELN polymorphisms
Variables Univariate analysis
MMP2 rs243865 0.7 (0.52-0.93)
T allele
MMP3 rs3025058 1.61 (1.13-2.33)
5A allele
MMP13 rs2252070 1.65 (1.11-2.46)
GG genotype
ELN rs2071307 0.69 (0.51-0.92)
A allele
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary
aAdjusted for age, gender, hypertension, diabetes mellitus, dyslipidemia, smdant result might be due, at least in part, to the deviation lrom the HWE in the control subjects and the lower
ncidence of previous CAD andCVD in a previous article.21
oreover, in our study, patients had markedly larger AAA
iameters with respect to the previously published papers21
52.4 	 10.5 mm vs 35.7 	 6.8 mm).
MMP3 or stromelysin-1 is capable of degrading pro-
eoglycan, fibronectin, laminin, and type IV collagen. A
investigated polymorphisms in AAA patients and
Genotypes (%) Minor
allele
frequency PControl subjects (n  423)
AA(24.8) AG(51.3) GG(23.8) G  .495 1
CC(74.6) CT(23.1) TT(2.2) T  .138 .524c
CC(56.3) CT(37.6) TT(6.1) T  .249 .023c
GG(61.8) GA(33.4) AA(4.7) A  0.215 .296c
5A/5A
(21.9)
5A/6A
(50.8)
6A/6A
(27.3)
6A  0.572 .013b
GG(72.5) GA(23.9) AA(3.6) A  0.156 .159a
CC(94.9) CT(4.8) TT(0.3) T  .027 1
AA(76.9) AG(21.1) GG(1.9) G  .125 .719b
AA(40.0) AG(45.9) GG(14.1) G  .371 .023b
TT(96.8) CT(3.2) CC(0.0) C  .016 .0001a
TT(46.1) CT(44.1) CC(9.8) C  .318 .264b
GG(31.3) GA(51.8) AA(16.9) A  0.428 .022c
rrection.
rs243865 MMP2, rs3025058 MMP3, rs2252070
P Multivariate analysisa P
.013 0.55 (0.34-0.85) .007
.007 1.82 (1.04-3.12) .034
.013 2.14 (1.18-3.86) .012
.012 0.64 (0.41-0.99) .046
.
habit, and COPD.he 12
or
le
ency
95
52
96
.180
.462
.146
24
24
33
00
59
.382
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gion has been extensively investigated. The 5A/6A poly-
morphism is located within the interleukin-1 responsive
element. This sequence variant arises from the insertion of
an adenine nucleotide at position 1612 relative to the
start of transcription, resulting in the wild-type allele having
a run of five adenine nucleotide (5A) and the less common
allele having six adenine nucleotides (6A). In in vitro ex-
periments, the 5A allelic promoter had a greater activity in
driving gene expression than the 6A allelic promoter.22
Studies of the levels of MMP3 mRNA and protein, in ex
vivo tissues, including vascular tissues from individuals of
different genotypes for the 5A/6A polymorphism, showed
that the levels were highest in 5A homozygotes, interme-
diate in heterozygotes and lowest in 6A homozygotes.23
Our study shows the importance of the risk factor of the
5A/6A polymorphism in the pathogenesis of AAA, proba-
bly due to its effect on the gene expression level.22 Previous
studies showed that the 5A allele occurred more frequently
in AAA patients,24 or in AAA patients with family history of
AAA.11 A higher frequency of the 5A allele in AAA patients
was also found in one small Finnish study although it failed
to achieve statistical significance after correction for multi-
ple testing.25
In the literature, only one study has investigated the
role of the polymorphism77A/G in the promoter region
of MMP-13 in conferring genetic susceptibility to AAA,
but failed to demonstrate any association.11 Our data, on
the contrary, demonstrated that this polymorphisms is sig-
nificantly and independently associated with AAA. A possi-
ble explanation for this discrepancy might be due to the
inclusion in the previous study11 of AAA patients with
family history of AAA or ethnic variations. On the other
hand, previous studies demonstrated that MMP-13 is ex-
Table V. Genotype distribution of the five polymorphism
atherosclerotic localizations
SNP
Genotypes (%)
AAA patients without other atherosclerotic
localizations
(n  118)
MMP2
rs243865 CC (64.4) CT  TT (35
MMP3
rs3025058 5A/5A5A/6A (79.6) 6A/6A (20.4
MMP-13
rs2252070 AA (82.9) AG  GG (17
TIMP1
rs4898 TT (100.0) CT  CC (0.
ELN
rs2071307 GG (38.3) GA  AA (61
AAA, Abdominal aortic aneurysm; SNP, single nucleotide polymorphism.
aP  according to the additive model.
bP  according to the recessive model.
cP  according to the dominant model.pressed at elevated levels in human aortic tissue.26 MMP13 tr collagenase 3 has a limited tissue distribution and a
ighly regulated pattern of expression. MMP-13 is active
gainst types I and III collagens asMMP1 andMMP-8, but
t is also capable of degrading the type-II collagen predom-
nating in cartilage. MMP-13 is further distinguished from
ther interstitial collagenases by its activity against gelatin,
roteoglycans, tenascin, fibronectin, and type IV collagen,
s well as its capacity to activate latent pro-MMPs. This
road substrate specificity makes MMP-13 one of the most
otent of the matrix-degrading metalloenzymes character-
zed to date. Our data are in keeping with previous studies
emonstrating that MMP-13 is consistently expressed in
ffected human aortic tissue and that MMP-13 mRNA is
xpressed to a greater degree in AAA compared with ath-
rosclerotic aorta.26 The 77G/A polymorphism is asso-
iated with an altered transcriptional activity: the con-
tructs with A nucleotide has approximately twice as
uch transcriptional activity as the constructs with G
ucleotide in the same position.27 The observed associ-
tion could be attributed not only to the presence of
educed level of MMP-13 per se, determined by the GG
enotype, but to a possible alteration of the balance
etween different MMPs.
Our data have not shown a role in AAA pathogenesis of
he 1562 C/T promoter polymorphism in the MMP9.
ur result is consistent with several literature data.11,25,28
TIMP1 regulates the activity of MMPs, preferentially
nhibiting their activity. Our data demonstrated that the
434T polymorphism in TIMP1 is protective for AAA.
he C434T is a same-sense polymorphism (Phe124Phe);
he significant association with AAA might be due to the
resence of the causal polymorphism in linkage disequilib-
ium. Two studies evaluated the role of polymorphisms in
ciated with AAA in patients with and without other
Genotypes (%)
P
AAA patients with other atherosclerotic
localizations
(n  305)
CC (65.7) CT  TT (34.3) .821c
5A/5A5A/6A (81.6) 6A/6A (18.4) .641b
AA (76.3) AG  GG (23.7) .137b
TT (100.0) CT  CC (0.0) —
GG (41.3) GA  AA (58.7) .550cs asso
.6)
)
.1)
0)
.7)his gene in the AAA11,13; one small study did not find
e
a
A
l
o
f
A
t
a
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tion in the subgroup of patients without family history of
AAA.11
ELN is one of the major determinants of arterial dis-
tensibility of large blood vessels and one of the principal
components of elastic fibers of the media of arteries. Several
polymorphisms of the ELN gene have been described.
Tromp and coworkers identified an A-to-G polymorphism
in exon 16 resulting in an amino acid substitution
(Ser422Gly).29 Ogata and coworkers observed that this
polymorphism in ELN was associated with AAA, in partic-
Table VI. Polymorphisms investigated in relation to AAA
SNP ID
AAA vs
control subjects (N)
MMP1 387/425
rs1799750
(1607G/GG) 423/423
MMP2 678/659
rs243865
(1306C/T) 423/423
rs2285053
(735C/T) 423/423
rs243866
(1575G/A) 423/423
MMP3 405/405
rs3025058
(1612 5A/6A) 387/425
47/174
423/423
MMP9 387/425
rs3918242
(1562C/T) 414/203
47/174
676/649
423/423
MMP10 387/425
rs486055
(A180G-Lys53Arg) 423/423
MMP12 387/425
rs2276109
(82A/G) 423/423
MMP13 387/425
rs2252070
(77A/G) 423/423
TIMP1 84/51
rs4898
(C434T-Phe124Phe) 387/425
423/423
TIMP3 387/425
rs9619311
(1296T/C) 423/423
ELN 387/425
rs2071307
(G1355A-Ser422Gly) 99/225
423/423
AAA, Abdominal aortic aneurysm; SNP, single nucleotide polymorphism.
aRefers to this article.ular in subjects with family history of disease.11 Our data pxtend this result showing that the A allele is a significant
nd independent protector factor for AAA.
For polymorphisms independently associated with
AA in this study, we performed ameta-analysis. Even with
imitations due to the absence or not complete information
f some published studies (eg, confounding variables), we
ound a significant association with an increased risk of
AA for MMP3 and MMP-13 polymorphisms and a trend
owards a decreased risk of AAA for 1306 C/T MMP2
nd ELN polymorphisms.
Our study did not show any association of the polymor-
ence
Association
with AAA Reference
No Ogata et al11
No Saracini et ala
No Smallwood et al21
Yes Saracini et ala
No Saracini et ala
No Saracini et ala
Yes Deguara et al24
No Ogata et al11
Yes in subgroup analysis
Yes (trend) Yoon et al25
Yes Saracini et ala
No Ogata et al11
Yes Jones et al35
No Yoon et al25
No Smallwood et al28
No Saracini et ala
No Ogata et al11
No Saracini et ala
No Ogata et al11
No Saracini et ala
No Ogata et al11
Yes Saracini et ala
No Wang et al13
No Ogata et al11
Yes in subgroup analysis
Yes Saracini et ala
No Ogata et al11
No Saracini et ala
No Ogata et al11
Yes in subgroup analysis
No Massart et al36
Yes Saracini et alaincidhisms with aortic diameters. Our data are consistent with
p
p
G
A
C
A
D
W
C
F
S
O
O
R
1
1
1
1
1
1
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MMP-2, 1171 5A/6A MMP3, 1562 C/T MMP-9,
and 82 A/G MMP-12 polymorphisms with AAA expan-
sion.21,30 Nevertheless, one of the limitations of our study
is its inadequacy to evaluate the influence of the investi-
gated polymorphisms on the progression of the disease, as
our study was conducted on patients admitted to the
observation of Vascular Surgery Unit for repair of the AAA.
Due to the presence of high prevalence of traditional
cardiovascular risk factors and other clinical manifestations
of atherosclerosis in AAA patients (CAD, CVD, and
POAD), our data, at present, cannot definitely indicate
whether the identified polymorphisms represent genetic
markers of atherosclerosis or AAA development. On the
other hand, AAA is strongly associated with atherosclero-
sis.31 Even if our study was not aimed to investigate sub-
group differences among AAA patients, in our population,
no differences in the distribution of polymorphisms associ-
ated with AAA were observed between patients with or
without other atherosclerotic localizations. Interestingly,
patients with AAA plus other clinical manifestations of
atherosclerosis were older and showed higher prevalence of
different cardiovascular risk factors, in particular hyperten-
sion and COPD. Contrasting data and not for all the
polymorphisms investigated in this study are available in the
literature concerning association with other atherosclerotic
diseases. Concerning 5A/6A MMP3, although data from
some individual studies suggested a relationship with CAD,
the result of a recent meta-analysis argued against an asso-
ciation of this polymorphism with atherosclerotic coronary
diseases.32 To better comprehend whether these polymor-
phisms represent markers of atherosclerosis or AAA, further
studies in “pure” CAD or CVD patients comparable for
gender and age to AAA patients are warranted.
In conclusion, present data have identified important
polymorphisms in MMP2, MMP3, MMP-13, and ELN
genes as genetic markers of AAA and underline the need to
concentrate our efforts in studying the role of these markers
in the aneurysmal disease to improve the understanding of
its pathophysiology and pathogenesis.
For each gene, there are further SNPs that could be
considered to better identify the susceptibility alleles. Due
to the fundamental clinical implications, further studies on
larger populations are needed (1) to confirm the role of the
polymorphisms emerged associated with AAA in this study,
(2) to evaluate the role of other polymorphisms in the same
genes allowing a finer identification of the susceptibility
alleles, and (3) to study other candidate genes involved in
ECM remodeling as predictor of AAA disease. The poly-
morphisms that resulted susceptibility factor for AAA in
this study could be part of a future panel, involving other
important genetic variants, such as those identified in re-
cent genome wide association studies for AAA in chromo-
some 9p21 and 9q33.33,34 The identification of genetic
susceptibility factors and the evaluation of their role per se
or in combination is fundamental to design gene-based
clinical studies in the future to validate diagnostic or prog-
nostic scores based on clinical, biochemical, genetic, androteomic information to be applied in the everyday clinical
ractice.
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January 2012179.e1 Saracini et alTable A, online only. Oligonucleotide designs for PCR a
SNP ID Panel Oligo type
MMP1
rs1799750 GA PCRU ATTC
PCRL TGAT
SNPU CGTG
MMP2
rs2285053 CT PCRU TTTG
PCRL TGGG
SNPU GGCT
rs243865 CT PCRU CCAT
PCRL TGAC
SNPU AGGG
rs243866 GA PCRU ACAA
PCRL AACA
SNPU AGAG
MMP10
rs486055 GA PCRU ATTAG
PCRL CAAC
SNPU GACC
MMP-12
rs2276109 GA PCRU TAATT
PCRL TAAG
SNPU AGCG
MMP-13
rs2252070 GA PCRU TTTAT
PCRL ATTAC
SNPU CGAC
TIMP1
rs4898 CT PCRU TTTC
PCRL TAGG
SNPU AGAT
TIMP3
rs96193114 CT PCRU AGTT
PCRL GTAG
SNPU AGAG
ELN
rs17855987 GA PCRU TTTG
PCRL GGAA
SNPU GGAT
PCR, Polymerase chain reaction; PCRU, oligonucleotide forward; PCRL, o
aAll oligonucleotide sequences are in 5=–3= direction.nd primer extension reactionsa
Sequence
TTCTTACCCTCTTGAACTCA
ATCTTACTCATAAACAATACTTCAGTA
CCGCTCGTGATAGAATAAATTGTAGTTAAATAATTAGAAAG
TGACCTCTATCKTATTAAACCA
TAAAATGAGGCTGAGA
ATGATTCGCAATGCTTTCATCCTGTGACCGAGAATGCGGAC
TGTCAATGTTCCCTAAA
TTCAGCCCCTAAACTAGTAA
TCTCTACGCTGACGATTCCCCATATTCCCCACCCAGCACTC
GCCTGAACTTGTCTGAA
GTTTGAGAAGTAAGGTCAGG
CGAGTGACGCATACTATAGCTGTGATGATCAAGACATAATC
CAATACCTAGAAAAGTACTACAACC
CCAAGGAACTTCTGC
TGGGTGTCGATACCTAGAAAAGGATGTGAAACAGTTTAGAA
GATCCATTGTCGTCTGA
TTCCTGAACTGTTCCTCTTTAT
ATCTGCGAGACCGTATGATAGATCAAGGGATGATATCAACT
ATTTCCCTCAAATTCTACCAC
CTTTACTTTTATAGGCCTGC
TGTAGGTGCGTAACTCTAAGCATGTTTACCTTCAAGTGACT
TCCTTAGGAAAACTGCAG
TCTTGGTGAAGCCC
AGAGTCGATGCCAGCTTCTTGCACATCACTACCTGCAGTTT
TTGGATCAGCTCACCC
AAAGGCAAGAGGAAGTGG
CGAGTGACGCATACTACAAATCCCTTGCTGAAGGGTGRAGC
GTGTCGGAGTCGGA
ATGCCAACTCCCGG
GGCGTTCCGTCCTATTTATCCCTGGAGTCGCAGGTGTCCCT
ligonucleotide reverse; SNPU, oligonucleotide primer extension.
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Volume 55, Number 1 Saracini et al 179.e2Table B, online only. PCR and hybridization oligonucleotide for electronic microchip analysis
SNP ID Type of oligonucleotides Sequences Ta (°C) Tb (°C)
MMP3 Forward PCR 5=-gattacagacatgggtcacg-3= 61
rs3025058 Reverse PCR 5=-biotin-gaattcacatcactgccacc-3=
Stabilizer 5=-atgtcttgtcctgattgaaatacagggaaaatatttggcc-3= 48
Reporter WT 5=-Cy3-ctgagtccgaacattgagtttggggggaaaaacc-3=
Reporter MUT 5=-Cy5-gcagtatatcgcttgacaccggggggaaaaaacc-3=
MMP9 Forward PCR 5=-biotin-gcctggcacatagtaggccc-3= 66
rs3918242 Reverse PCR 5=-cttcctagccagccggcatc-3=
Stabilizer 5=-tgcgccaccacgcctggctaaattttttgtatt-3= 38
Reporter WT 5=-Cy3-ctgagtccgaacattgagaaggtattataggcg-3=
Reporter MUT 5=-Cy5-gcagtatatcgcttgacaaatggtattataggca-3=PCR, Polymerase chain reaction; Ta, annealing temperature; Tb, optimal temperature for thermal stringency.
